Incidence and Severity of Lymphoedema following Limb Salvage of Extremity Soft Tissue Sarcoma.
Identifieur interne : 002338 ( PubMed/Corpus ); précédent : 002337; suivant : 002339Incidence and Severity of Lymphoedema following Limb Salvage of Extremity Soft Tissue Sarcoma.
Auteurs : Daniel Friedmann ; Jay S. Wunder ; Peter Ferguson ; Brian O'Sullivan ; David Roberge ; Charles Catton ; Carolyn Freeman ; Neil Saran ; Robert E. TurcotteSource :
- Sarcoma [ 1369-1643 ] ; 2011.
Abstract
Background and Purpose. Lymphoedema is a serious complication following limb salvage for extremity soft tissue sarcomas (STSs) for which little is known. We aimed to evaluate its incidence, its, severity and its associated risk factors. Material and Method. Patient and tumor characteristics, treatment modalities and complications and functional outcomes (MSTS 1987, TESS), and lymphoedema severity (Stern) were all collected from prospective databases. Charts were retrospectively abstracted for BMI and comorbidities. Results. There were 289 patients (158 males). Mean age was 53 (16-88). Followup ranged between 12 and 60 months with an average of 35 and a median of 36 months. Mean BMI was 27.4 (15.8-52.1). 72% had lower extremity tumors and 38% upper extremity. Mean tumor size was 8.1 cm (1.0-35.6 cm). 27% had no adjuvant radiation, 62% had 50 Gy, and 11% received 66 Gy. The incidence of lymphoedema was 28.8% (206 none, 58 mild, 22 moderate, 3 severe, and 0 very severe). Mean MSTS score was 32 (11-35) and TESS was 89.4 (32.4-100). Radiation dose was significantly correlated with tumor size > 5 cm (P = 0.0001) and TESS score (P = 0.001), but not MSTS score (P = 0.090). Only tumor size > 5 cm and depth were found to be independent predictors of significant lymphoedema. Conclusion. Nine percent of STS patients in our cohort developed significant (grade ≥ 2) lymphoedema. Tumor size > 5 cm and deep tumors were associated with an increased occurrence of lymphoedema but not radiation dosage.
DOI: 10.1155/2011/289673
PubMed: 22190861
Links to Exploration step
pubmed:22190861Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Incidence and Severity of Lymphoedema following Limb Salvage of Extremity Soft Tissue Sarcoma.</title><author><name sortKey="Friedmann, Daniel" sort="Friedmann, Daniel" uniqKey="Friedmann D" first="Daniel" last="Friedmann">Daniel Friedmann</name><affiliation><nlm:affiliation>Division of Orthopedic Surgery, McGill University Health Centre, Montreal, QC, Canada H3G 1A4.</nlm:affiliation></affiliation></author><author><name sortKey="Wunder, Jay S" sort="Wunder, Jay S" uniqKey="Wunder J" first="Jay S" last="Wunder">Jay S. Wunder</name></author><author><name sortKey="Ferguson, Peter" sort="Ferguson, Peter" uniqKey="Ferguson P" first="Peter" last="Ferguson">Peter Ferguson</name></author><author><name sortKey="O Sullivan, Brian" sort="O Sullivan, Brian" uniqKey="O Sullivan B" first="Brian" last="O'Sullivan">Brian O'Sullivan</name></author><author><name sortKey="Roberge, David" sort="Roberge, David" uniqKey="Roberge D" first="David" last="Roberge">David Roberge</name></author><author><name sortKey="Catton, Charles" sort="Catton, Charles" uniqKey="Catton C" first="Charles" last="Catton">Charles Catton</name></author><author><name sortKey="Freeman, Carolyn" sort="Freeman, Carolyn" uniqKey="Freeman C" first="Carolyn" last="Freeman">Carolyn Freeman</name></author><author><name sortKey="Saran, Neil" sort="Saran, Neil" uniqKey="Saran N" first="Neil" last="Saran">Neil Saran</name></author><author><name sortKey="Turcotte, Robert E" sort="Turcotte, Robert E" uniqKey="Turcotte R" first="Robert E" last="Turcotte">Robert E. Turcotte</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2011">2011</date><idno type="RBID">pubmed:22190861</idno><idno type="pmid">22190861</idno><idno type="doi">10.1155/2011/289673</idno><idno type="wicri:Area/PubMed/Corpus">002338</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002338</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Incidence and Severity of Lymphoedema following Limb Salvage of Extremity Soft Tissue Sarcoma.</title><author><name sortKey="Friedmann, Daniel" sort="Friedmann, Daniel" uniqKey="Friedmann D" first="Daniel" last="Friedmann">Daniel Friedmann</name><affiliation><nlm:affiliation>Division of Orthopedic Surgery, McGill University Health Centre, Montreal, QC, Canada H3G 1A4.</nlm:affiliation></affiliation></author><author><name sortKey="Wunder, Jay S" sort="Wunder, Jay S" uniqKey="Wunder J" first="Jay S" last="Wunder">Jay S. Wunder</name></author><author><name sortKey="Ferguson, Peter" sort="Ferguson, Peter" uniqKey="Ferguson P" first="Peter" last="Ferguson">Peter Ferguson</name></author><author><name sortKey="O Sullivan, Brian" sort="O Sullivan, Brian" uniqKey="O Sullivan B" first="Brian" last="O'Sullivan">Brian O'Sullivan</name></author><author><name sortKey="Roberge, David" sort="Roberge, David" uniqKey="Roberge D" first="David" last="Roberge">David Roberge</name></author><author><name sortKey="Catton, Charles" sort="Catton, Charles" uniqKey="Catton C" first="Charles" last="Catton">Charles Catton</name></author><author><name sortKey="Freeman, Carolyn" sort="Freeman, Carolyn" uniqKey="Freeman C" first="Carolyn" last="Freeman">Carolyn Freeman</name></author><author><name sortKey="Saran, Neil" sort="Saran, Neil" uniqKey="Saran N" first="Neil" last="Saran">Neil Saran</name></author><author><name sortKey="Turcotte, Robert E" sort="Turcotte, Robert E" uniqKey="Turcotte R" first="Robert E" last="Turcotte">Robert E. Turcotte</name></author></analytic><series><title level="j">Sarcoma</title><idno type="eISSN">1369-1643</idno><imprint><date when="2011" type="published">2011</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Background and Purpose. Lymphoedema is a serious complication following limb salvage for extremity soft tissue sarcomas (STSs) for which little is known. We aimed to evaluate its incidence, its, severity and its associated risk factors. Material and Method. Patient and tumor characteristics, treatment modalities and complications and functional outcomes (MSTS 1987, TESS), and lymphoedema severity (Stern) were all collected from prospective databases. Charts were retrospectively abstracted for BMI and comorbidities. Results. There were 289 patients (158 males). Mean age was 53 (16-88). Followup ranged between 12 and 60 months with an average of 35 and a median of 36 months. Mean BMI was 27.4 (15.8-52.1). 72% had lower extremity tumors and 38% upper extremity. Mean tumor size was 8.1 cm (1.0-35.6 cm). 27% had no adjuvant radiation, 62% had 50 Gy, and 11% received 66 Gy. The incidence of lymphoedema was 28.8% (206 none, 58 mild, 22 moderate, 3 severe, and 0 very severe). Mean MSTS score was 32 (11-35) and TESS was 89.4 (32.4-100). Radiation dose was significantly correlated with tumor size > 5 cm (P = 0.0001) and TESS score (P = 0.001), but not MSTS score (P = 0.090). Only tumor size > 5 cm and depth were found to be independent predictors of significant lymphoedema. Conclusion. Nine percent of STS patients in our cohort developed significant (grade ≥ 2) lymphoedema. Tumor size > 5 cm and deep tumors were associated with an increased occurrence of lymphoedema but not radiation dosage.</div></front></TEI><pubmed><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">22190861</PMID><DateCreated><Year>2011</Year><Month>12</Month><Day>22</Day></DateCreated><DateCompleted><Year>2012</Year><Month>08</Month><Day>23</Day></DateCompleted><DateRevised><Year>2017</Year><Month>02</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1369-1643</ISSN><JournalIssue CitedMedium="Internet"><Volume>2011</Volume><PubDate><Year>2011</Year></PubDate></JournalIssue><Title>Sarcoma</Title><ISOAbbreviation>Sarcoma</ISOAbbreviation></Journal><ArticleTitle>Incidence and Severity of Lymphoedema following Limb Salvage of Extremity Soft Tissue Sarcoma.</ArticleTitle><Pagination><MedlinePgn>289673</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1155/2011/289673</ELocationID><Abstract><AbstractText>Background and Purpose. Lymphoedema is a serious complication following limb salvage for extremity soft tissue sarcomas (STSs) for which little is known. We aimed to evaluate its incidence, its, severity and its associated risk factors. Material and Method. Patient and tumor characteristics, treatment modalities and complications and functional outcomes (MSTS 1987, TESS), and lymphoedema severity (Stern) were all collected from prospective databases. Charts were retrospectively abstracted for BMI and comorbidities. Results. There were 289 patients (158 males). Mean age was 53 (16-88). Followup ranged between 12 and 60 months with an average of 35 and a median of 36 months. Mean BMI was 27.4 (15.8-52.1). 72% had lower extremity tumors and 38% upper extremity. Mean tumor size was 8.1 cm (1.0-35.6 cm). 27% had no adjuvant radiation, 62% had 50 Gy, and 11% received 66 Gy. The incidence of lymphoedema was 28.8% (206 none, 58 mild, 22 moderate, 3 severe, and 0 very severe). Mean MSTS score was 32 (11-35) and TESS was 89.4 (32.4-100). Radiation dose was significantly correlated with tumor size > 5 cm (P = 0.0001) and TESS score (P = 0.001), but not MSTS score (P = 0.090). Only tumor size > 5 cm and depth were found to be independent predictors of significant lymphoedema. Conclusion. Nine percent of STS patients in our cohort developed significant (grade ≥ 2) lymphoedema. Tumor size > 5 cm and deep tumors were associated with an increased occurrence of lymphoedema but not radiation dosage.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Friedmann</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Division of Orthopedic Surgery, McGill University Health Centre, Montreal, QC, Canada H3G 1A4.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wunder</LastName><ForeName>Jay S</ForeName><Initials>JS</Initials></Author><Author ValidYN="Y"><LastName>Ferguson</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>O'Sullivan</LastName><ForeName>Brian</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Roberge</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Catton</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Freeman</LastName><ForeName>Carolyn</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Saran</LastName><ForeName>Neil</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Turcotte</LastName><ForeName>Robert E</ForeName><Initials>RE</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>11</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Egypt</Country><MedlineTA>Sarcoma</MedlineTA><NlmUniqueID>9709257</NlmUniqueID><ISSNLinking>1357-714X</ISSNLinking></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2002 Nov 15;20(22):4472-7</RefSource><PMID Version="1">12431971</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Acta Oncol. 2007;46(8):1138-42</RefSource><PMID Version="1">17851861</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Plast Surg. 2007 Oct;59(4):464-72</RefSource><PMID Version="1">17901744</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Radiat Oncol Biol Phys. 1991 Nov;21(6):1493-9</RefSource><PMID Version="1">1938558</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Breast Cancer Res Treat. 2008 Jul;110(1):19-37</RefSource><PMID Version="1">17899373</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2008 Jul 20;26(21):3536-42</RefSource><PMID Version="1">18640935</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer. 2010 Nov 15;116(22):5138-49</RefSource><PMID Version="1">20665892</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Surg Oncol. 1991 Dec;48(4):224-31</RefSource><PMID Version="1">1745046</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Acta Oncol. 2003;42(5-6):516-31</RefSource><PMID Version="1">14596510</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Radiat Oncol Biol Phys. 1995 Jul 15;32(4):977-85</RefSource><PMID Version="1">7607972</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Surg. 2006 Feb;191(2):230-4</RefSource><PMID Version="1">16442951</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Qual Life Res. 1997 Jul;6(5):373-84</RefSource><PMID Version="1">9290304</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Cancer. 1991;27(12):1567-74</RefSource><PMID Version="1">1782065</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nurs Res. 2008 Nov-Dec;57(6):416-25</RefSource><PMID Version="1">19018216</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Qual Life Res. 2006 Nov;15(9):1439-46</RefSource><PMID Version="1">16732468</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2002 Jun 29;359(9325):2235-41</RefSource><PMID Version="1">12103287</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Curr Treat Options Oncol. 2004 Dec;5(6):477-88</RefSource><PMID Version="1">15509481</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Breast Cancer Res Treat. 2009 Jan;113(2):383-91</RefSource><PMID Version="1">18297429</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lymphology. 2010 Sep;43(3):118-27</RefSource><PMID Version="1">21226414</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Semin Radiat Oncol. 2003 Jul;13(3):214-25</RefSource><PMID Version="1">12903011</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Radiother Oncol. 2005 Apr;75(1):48-53</RefSource><PMID Version="1">15948265</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Semin Radiat Oncol. 1999 Oct;9(4):360-8</RefSource><PMID Version="1">10516383</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Radiat Oncol Biol Phys. 2007 Mar 1;67(3):847-56</RefSource><PMID Version="1">17161553</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Qual Life Res. 1996 Oct;5(5):508-16</RefSource><PMID Version="1">8973131</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer. 1998 Dec 15;83(12 Suppl American):2788-97</RefSource><PMID Version="1">9874399</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer. 2006 Nov 15;107(10):2455-61</RefSource><PMID Version="1">17036354</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Radiother Oncol. 2009 Oct;93(1):125-30</RefSource><PMID Version="1">19604591</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Nurs. 2008 Jun;17(11):1450-9</RefSource><PMID Version="1">18482142</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Radiat Oncol Biol Phys. 2010 Jul 15;77(4):1191-7</RefSource><PMID Version="1">20056340</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ostomy Wound Manage. 2007 May;53(5):16-29</RefSource><PMID Version="1">17551172</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Surg Clin North Am. 2009 Feb;89(1):235-47, x</RefSource><PMID Version="1">19186238</PMID></CommentsCorrections></CommentsCorrectionsList><OtherID Source="NLM">PMC3236348</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>08</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2011</Year><Month>09</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>09</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>12</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>12</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>12</Month><Day>23</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22190861</ArticleId><ArticleId IdType="doi">10.1155/2011/289673</ArticleId><ArticleId IdType="pmc">PMC3236348</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002338 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 002338 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:22190861
|texte= Incidence and Severity of Lymphoedema following Limb Salvage of Extremity Soft Tissue Sarcoma.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:22190861" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |